Provided by Tiger Trade Technology Pte. Ltd.

Vanda Pharmaceuticals

5.09
+0.05000.99%
Post-market: 5.160.0700+1.38%19:30 EDT
Volume:701.23K
Turnover:3.58M
Market Cap:307.76M
PE:-1.10
High:5.17
Open:5.10
Low:5.05
Close:5.04
52wk High:9.94
52wk Low:4.27
Shares:60.46M
Float Shares:47.66M
Volume Ratio:0.96
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6291
EPS(LYR):-3.7413
ROE:-77.81%
ROA:-22.38%
PB:1.40
PE(LYR):-1.36

Loading ...

Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab

TIPRANKS
·
Jul 17

Vanda Says EMA Panel Backs Orphan Drug Designation for Imsidolimab in Generalized Pustular Psoriasis

Reuters
·
Jul 17

Vanda Pharmaceuticals - Imsidolimab Bla for Gpp Under FDA Review with Target Action Date December 12, 2026

THOMSON REUTERS
·
Jul 17

Vanda Pharmaceuticals - Announces Ema Positive Opinion for Orphan Drug Designation of Imsidolimab for Gpp

THOMSON REUTERS
·
Jul 17

Vanda Says FDA Grants Rare Pediatric Disease Designation for CMT2S Therapy Vca-894a

Reuters
·
Jul 08

Vanda Pharmaceuticals Inc: Advancing Development of Its Investigational Therapy for Cmt2s

THOMSON REUTERS
·
Jul 08

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-marie-tooth Disease Type 2S

THOMSON REUTERS
·
Jul 08

Vanda Pharmaceuticals SVP, General Counsel and Secretary Daniel McGuire files initial beneficial ownership statement

Reuters
·
Jun 09

Vanda Pharmaceuticals Inc - Japan Grants Orphan Drug Designation to Imsidolimab for Generalized Pustular Psoriasis

THOMSON REUTERS
·
May 27

Japan health ministry grants orphan drug status to Vanda’s imsidolimab for pustular psoriasis

Reuters
·
May 27

Vanda Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11

Vanda Pharmaceuticals Bets Big on Growth Pipeline

TIPRANKS
·
May 08

Vanda Pharmaceuticals to present at Bank of America Securities Global Health Care Conference

Reuters
·
May 08

Vanda Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07

Vanda Pharma Q1 EPS $(0.82) Misses $(0.69) Estimate, Sales $51.718M Miss $54.978M Estimate

Benzinga Earnings
·
May 07

Vanda Q1 FY26 net loss widens to $48.6 million; revenue rises 3% to $51.7 million

Reuters
·
May 07

BRIEF-Vanda Pharmaceuticals Q1 EPS USD -0.82

Reuters
·
May 07

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 07

Vanda Pharmaceuticals Q1 Revenue USD 51.718 Million VS. Ibes Estimate USD 55 Million

THOMSON REUTERS
·
May 07

Vanda Pharmaceuticals Outlook 2026 Total Revenues $240 Mln - $290 Million

THOMSON REUTERS
·
May 07